JP MORGAN/CALL/ELI LILLY & CO/920/0.1/21.06.24 | Market Closed - Börse Stuttgart 01:11:35 14/06/2024 pm IST | ||
| 0.3 EUR | +36.36% |
|
| Current month | +66.67% | ||
| 1 month | +289.61% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 14/24/14 | 0.3 | +36.36% |
| 13/24/13 | 0.22 | -21.43% |
| 12/24/12 | 0.28 | +27.27% |
| 11/24/11 | 0.22 | -12.00% |
| 10/24/10 | 0.25 | +92.31% |
Delayed Quote Börse Stuttgart
Last update June 14, 2024 at 01:11 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | J.P. Morgan |
| WKN | JB4NTX |
| ISIN | DE000JB4NTX4 |
| Date issued | 18/10/2023 |
| Strike | 920 $ |
| Maturity | 21/06/2024 (6 Days) |
| Parity | 10 : 1 |
| Emission price | 0.79 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.16 € |
|---|---|
| Lowest since issue | 0.075 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
878.4
USD
Average target price
855.4
USD
Spread / Average Target
-2.63%
- Stock Market
- Warrants
- Warrant
